Scilex Holding Company (SCLX) Revenue History
Annual and quarterly revenue from 2020 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
SCLX Revenue Analysis (2020–2024)
As of March 1, 2026, Scilex Holding Company (SCLX) generated trailing twelve-month (TTM) revenue of $40.4 million, reflecting significant decline in growth of -26.8% year-over-year. The most recent quarter (Q3 2025) recorded $10.6 million in revenue, up 6.7% sequentially.
Looking at the longer-term picture, SCLX's historical revenue data shows a 3-year CAGR of +21.8%. The company achieved its highest annual revenue of $56.6 million in 2024, representing a new all-time high.
When compared to Healthcare sector peers including ABBV (+7.4% YoY), AMGN (+9.9% YoY), and GILD (+2.4% YoY), SCLX has underperformed the peer group in terms of revenue growth. Compare SCLX vs ABBV →
Peer Comparison
Compare SCLX's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| SCLXCurrent | $40M | -26.8% | - | -147.4% | |
| ABBV | $56.3B | +7.4% | +11.1% | 16.2% | |
| AMGN | $36.8B | +9.9% | +7.6% | 40.5% | |
| GILD | $28.8B | +2.4% | +5.1% | 5.8% | |
| NVO | $297.2B | +2.3% | +18.5% | 41.4% | |
| BIIB | $9.8B | +1.4% | -6.1% | 19.1% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $56.6M | +21.1% | $39.9M | 70.5% | $-83,396,000 | -147.4% |
| 2023 | $46.7M | +22.9% | $31.1M | 66.5% | $-105,431,000 | -225.6% |
| 2022 | $38.0M | +21.4% | $27.2M | 71.6% | $-50,634,000 | -133.1% |
| 2021 | $31.3M | +32.9% | $27.7M | 88.4% | $-35,838,000 | -114.4% |
| 2020 | $23.6M | - | $21.4M | 90.9% | $-35,258,000 | -149.7% |
See SCLX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SCLX Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare SCLX vs AGIO
See how SCLX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is SCLX's revenue growth accelerating or slowing?
SCLX revenue declined -26.8% year-over-year, contrasting with the 5-year CAGR of N/A. TTM revenue fell to $40M. This reverses the prior growth trend.
What is SCLX's long-term revenue growth rate?
Scilex Holding Company's 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of -26.8% is below this long-term average.
How is SCLX's revenue distributed by segment?
SCLX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2020-2024 are available for download. Segment mix reveals concentration and diversification trends.